So far, 2025 has proven to be a year of constant change within the life sciences space. A fluctuating political environment, an unpredictable economy and changes in laws and regulations have created uncertainties and confusion. But BakerHostetler’s Life Sciences Industry team is here to help by keeping you up to date on the plethora of changes so you can focus on other things – like your product, your research and your profit margin.
With that goal in mind, we are pleased to share the third issue of the BakerHostetler Life Sciences Newsletter, which includes the following important and timely content:
- Considering “Dexit”: A Comparative Review of Key Issues in the Corporate Laws of Delaware, Nevada and Texas
- FDA’s “PreCheck” Program: New Pathway to Acceleration of U.S. Drug Manufacturing
- FDA Launches New Priority Review Voucher Program for Biopharmas
- Is Major Health Legislation the Next Issue to be Addressed by Congress?
- Commerce Department Considering Changing Maintenance Fees to a Value-Based System
- Federal Circuit Decides Its First-Ever Derivation Proceeding
- Ongoing Disruptions in the U.S. Medical Products Supply Chain
- Passage of the One Big Beautiful Bill Act and Its Effect on Research and Development
- Q&A with Partner Bradley Pensyl, commercial litigator and a member of the Life Sciences Industry team
